FM
TPST icon

Fondren Management’s Tempest Therapeutics TPST Stock Holding History

Fondren Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-74
Closed -$217K – 90
2019
Q1 		$217K Buy
+74
New +$164K 0.17% 73

Other funds holding TPST

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
B
Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fondren Management's TPST Position: Q2 2019 in Review

Fondren Management sold out of Tempest Therapeutics (TPST) in Q2 2019, closing a stake of 74 shares — an estimated $217K sold.

Fondren Management first reported a position in TPST in Q1 2019 and held it in 1 quarter. The position peaked at $217K in Q1 2019. 38 funds tracked by Wall St. Rank hold TPST as of Q2 2019.

  • Fondren Management reported no remaining Tempest Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Fondren Management sold 74 Tempest Therapeutics shares in Q2 2019, an estimated $217K.
  • Fondren Management first reported a position in Tempest Therapeutics in Q1 2019 and held it in 1 quarter.
  • Fondren Management's Tempest Therapeutics position peaked at $217K in Q1 2019.
  • 38 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2019.

Based on Fondren Management's 13F filing for Q2 2019, filed 14 Aug 2019.